Please check your internet connection and try again.
# Clobazam (oral formulation)
## Overview
Clobazam is a 1,5-benzodiazepine utilized primarily as adjunctive therapy in the management of seizures. Unlike 1,4-benzodiazepines (e.g., diazepam, lorazepam), it possesses a unique chemical structure that may provide a different side-effect profile, though it remains a central nervous system depressant.
## Primary Indications
Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients ≥2 years.
## Adult Dosing
* **Initial:** 5–10 mg twice daily.
* **Titration:** Gradually increase every week based on tolerance and clinical response.
* **Maintenance:** Typically 20 mg/day (administered as 10 mg twice daily).
* **Maximum:** 40 mg/day (administered in two divided doses).
## Pediatric Dosing (≥2 years)
Dosing is weight-based.
* **≤30 kg:**
* Initial: 5 mg once daily.
* Titrate to target (clinical response): 10 mg twice daily.
* **>30 kg:**
* Initial: 10 mg once daily.
* Titrate to target (clinical response): 20 mg twice daily.
* **Maximum:** 40 mg/day.
## Dose Adjustments
* **Renal Impairment:** No specific adjustment defined, but use cautiously as pharmacokinetics may be altered.
* **Hepatic Impairment:** Reduce initial dosage and titrate very slowly. In severe hepatic impairment, clinical data are limited; use caution.
* **CYP2C19 Poor Metabolizers:** Clobazam levels may be significantly elevated; start at lower doses and titrate slowly.
## Contraindications
Hypersensitivity to clobazam or its components.
## Adverse Effects
* **Common:** Somnolence, sedation, lethargy, drooling (sialorrhea), constipation, fever, ataxia, and fatigue.
* **Serious:** Severe dermatological reactions (Stevens-Johnson syndrome/toxic epidermal necrolysis), respiratory depression, and increased risk of suicidal ideation or behavior.
## Key Drug Interactions
* **CNS Depressants (Opioids, alcohol, other benzodiazepines):** High risk of profound sedation, respiratory depression, coma, and death. Avoid concomitant use whenever possible.
* **CYP2C19 Inducers/Inhibitors:** Strong inhibitors (e.g., fluconazole, fluvoxamine) significantly increase levels of the active metabolite *N-desmethylclobazam*.
* **Oral Contraceptives:** May decrease effectiveness of hormonal contraceptives; consider alternative barrier methods.
## Monitoring
* **Safety:** Monitor for worsening depression, suicidal ideation, or unusual changes in mood or behavior.
* **Respiratory:** Monitor for signs of excessive sedation or respiratory distress, especially during initiation or dose increases.
* **Dermatological:** Discontinue immediately if any unexplained rash occurs.
## Clinical Pearls
* **Controlled Substance:** Schedule IV medication; monitor for potential abuse or dependence.
* **Discontinuation:** Must be tapered gradually to avoid withdrawal symptoms or status epilepticus.
* **Formulation:** Tablets can be crushed and mixed with applesauce; the oral suspension should be shaken well before use.
* **Active Metabolite:** The efficacy and adverse effect profile are largely driven by the active metabolite, *N-desmethylclobazam*, which has a long half-life.
***
*Disclaimer: This information is for educational purposes only. Clinical practice guidelines vary by institution and patient-specific factors. Always verify current prescribing information, package inserts, and local protocols before prescribing or administering medication.*
